Boston Family Office LLC Sells 466 Shares of Danaher Co. (NYSE:DHR)

Boston Family Office LLC lessened its holdings in Danaher Co. (NYSE:DHR) by 1.2% during the fourth quarter, Holdings Channel reports. The fund owned 36,963 shares of the conglomerate’s stock after selling 466 shares during the period. Boston Family Office LLC’s holdings in Danaher were worth $8,485,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of Danaher by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock worth $3,056,996,000 after acquiring an additional 315,446 shares during the period. Roundview Capital LLC boosted its stake in Danaher by 2.7% in the 4th quarter. Roundview Capital LLC now owns 36,953 shares of the conglomerate’s stock valued at $8,483,000 after purchasing an additional 958 shares during the period. HighPoint Advisor Group LLC grew its holdings in Danaher by 22.5% in the 4th quarter. HighPoint Advisor Group LLC now owns 15,205 shares of the conglomerate’s stock valued at $3,201,000 after buying an additional 2,790 shares in the last quarter. Family Legacy Inc. increased its position in Danaher by 2.6% during the 4th quarter. Family Legacy Inc. now owns 5,941 shares of the conglomerate’s stock worth $1,415,000 after buying an additional 151 shares during the period. Finally, Cannell & Spears LLC lifted its holdings in shares of Danaher by 63.5% during the fourth quarter. Cannell & Spears LLC now owns 383,294 shares of the conglomerate’s stock worth $87,985,000 after buying an additional 148,809 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 0.4 %

Shares of Danaher stock opened at $205.01 on Tuesday. The firm’s 50 day moving average is $213.91 and its 200 day moving average is $235.91. The firm has a market capitalization of $146.52 billion, a PE ratio of 38.83, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the firm earned $2.09 EPS. Equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several research reports. Royal Bank of Canada restated an “outperform” rating and issued a $277.00 price target (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Jefferies Financial Group decreased their target price on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a research report on Friday, March 14th. Raymond James reiterated a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Finally, Robert W. Baird lowered their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.